Abstract Background The Global COVID Vaccine Safety (GCoVS) Project, established in
2021 under the multinational Global Vaccine Data Network™(GVDN®), facilitates …

Summary Background Licensed mRNA COVID-19 vaccines require booster doses to sustain
SARS-CoV-2-specific responses, creating the need for novel, broadly immunogenic …

With the approval of the first vaccines against respiratory syncytial virus (RSV) and a novel
RSV‐neutralizing antibody, 2023 has been perceived as a game‐changing year in …

The long-term association between mRNA-based coronavirus disease 2019 (COVID-19)
vaccination and the development of autoimmune connective tissue diseases (AI-CTDs) …

In recent years, mRNA vaccine has achieved increasing interest owing to its high potency,
safety, ease of production, and low-cost manufacturing. Currently approved mRNA vaccines …

Pharmacovigilance plays a central role in safeguarding public health by continuously
monitoring the safety of vaccines, being critical in a climate of vaccine hesitancy, where …

At times of pandemics, such as the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection, the situation demands rapid development and production timelines of safe …

This narrative review aims to report the main clinical manifestations, therapeutic strategies,
outcomes, and complications of acute SARS-CoV-2 infection in childhood and to summarize …

The potential adverse effects of coronavirus disease 2019 (COVID-19) vaccinations raise
public concerns. Data from Taiwan's Vaccine Injury Compensation Program (VICP) can …

Background Vaccines are vital for public health, but concerns about adverse effects,
particularly myocarditis and pericarditis linked to COVID-19 vaccines-, persist. This study …